Impact of the COVID-19 pandemic on the incidence of healthcare-associated Clostridioides difficile infection in a tertiary healthcare facility in the Republic of Ireland
{"title":"Impact of the COVID-19 pandemic on the incidence of healthcare-associated Clostridioides difficile infection in a tertiary healthcare facility in the Republic of Ireland","authors":"Saied Ali, Sinead McDermott","doi":"10.1016/j.infpip.2023.100300","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><em>Clostridioides difficile</em> is the foremost cause of nosocomial infectious diarrhoea and one of the most prevalent healthcare associated infections (HAIs).</p></div><div><h3>Aims</h3><p>To investigate the impact of the coronavirus disease 2019 (COVID-19) pandemic on the incidence of healthcare associated <em>C. difficile</em> infection (HA-CDI).</p></div><div><h3>Methods</h3><p>A retrospective study was conducted from January 2019–December 2022 inclusive at a tertiary University Hospital in Dublin, Ireland. The study period was divided into COVID-19 and non-COVID-19 periods determined in tangent with the then national incidences of COVID-19 and number of hospitalized patients with COVID-19. Analyses looked at quantity of testing performed, incidence rates and antimicrobial consumption. An independent samples t-test was used to determine significance between groups.</p></div><div><h3>Results</h3><p>Between COVID-19 and non-COVID-19 periods, no statistically significant difference was observed among HA-CDI rates per 10,000 bed-days (2.1 cases vs 1.76 cases; <em>P</em>=0.34), consumption of defined daily doses per 100 bed-days of antimicrobials – all antimicrobials (83.36 vs 89.5; <em>P</em>=0.091), fluoroquinolones only (3.71 vs 4.46; <em>P</em>=0.067), third-generation cephalosporins only (4.17 vs 4.43; <em>P</em>=0.449), carbapenems only (3.28 vs 3.26; <em>P</em>=0.944) – or the number of <em>C. difficile</em> tests performed per 10,000 bed-days (321.81 tests vs 326.63 tests; <em>P</em>=0.696).</p></div><div><h3>Conclusions</h3><p>There was no difference in the incidence rates of HA-CDI between COVID-19 and non-COVID-19 periods at our institution.</p></div>","PeriodicalId":33492,"journal":{"name":"Infection Prevention in Practice","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection Prevention in Practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590088923000331","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Clostridioides difficile is the foremost cause of nosocomial infectious diarrhoea and one of the most prevalent healthcare associated infections (HAIs).
Aims
To investigate the impact of the coronavirus disease 2019 (COVID-19) pandemic on the incidence of healthcare associated C. difficile infection (HA-CDI).
Methods
A retrospective study was conducted from January 2019–December 2022 inclusive at a tertiary University Hospital in Dublin, Ireland. The study period was divided into COVID-19 and non-COVID-19 periods determined in tangent with the then national incidences of COVID-19 and number of hospitalized patients with COVID-19. Analyses looked at quantity of testing performed, incidence rates and antimicrobial consumption. An independent samples t-test was used to determine significance between groups.
Results
Between COVID-19 and non-COVID-19 periods, no statistically significant difference was observed among HA-CDI rates per 10,000 bed-days (2.1 cases vs 1.76 cases; P=0.34), consumption of defined daily doses per 100 bed-days of antimicrobials – all antimicrobials (83.36 vs 89.5; P=0.091), fluoroquinolones only (3.71 vs 4.46; P=0.067), third-generation cephalosporins only (4.17 vs 4.43; P=0.449), carbapenems only (3.28 vs 3.26; P=0.944) – or the number of C. difficile tests performed per 10,000 bed-days (321.81 tests vs 326.63 tests; P=0.696).
Conclusions
There was no difference in the incidence rates of HA-CDI between COVID-19 and non-COVID-19 periods at our institution.
背景艰难梭菌是医院感染性腹泻的主要原因,也是最常见的卫生保健相关感染之一。目的探讨2019冠状病毒病(COVID-19)大流行对卫生保健相关性艰难梭菌感染(HA-CDI)发生率的影响。方法回顾性研究于2019年1月至2022年12月在爱尔兰都柏林的一家三级大学医院进行。根据当时全国COVID-19发病率和住院患者人数,将研究期分为COVID-19期和非COVID-19期。分析着眼于所进行的检测数量、发病率和抗微生物药物消耗量。采用独立样本t检验确定组间显著性。结果在COVID-19与非COVID-19期间,HA-CDI发生率(每万床日2.1例vs 1.76例;P=0.34),每100个住院日使用规定每日剂量的抗菌素-所有抗菌素(83.36 vs 89.5;P=0.091),仅使用氟喹诺酮类药物(3.71 vs 4.46;P=0.067),仅使用第三代头孢菌素(4.17 vs 4.43;P=0.449),仅碳青霉烯类(3.28 vs 3.26;P=0.944)——或每10,000个床位日进行艰难梭菌测试的次数(321.81次测试对326.63次测试;P = 0.696)。结论我院新冠肺炎期间HA-CDI与非新冠肺炎期间HA-CDI发生率无差异。